JP2009280596A - 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ - Google Patents
精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ Download PDFInfo
- Publication number
- JP2009280596A JP2009280596A JP2009168383A JP2009168383A JP2009280596A JP 2009280596 A JP2009280596 A JP 2009280596A JP 2009168383 A JP2009168383 A JP 2009168383A JP 2009168383 A JP2009168383 A JP 2009168383A JP 2009280596 A JP2009280596 A JP 2009280596A
- Authority
- JP
- Japan
- Prior art keywords
- mirtazapine
- antipsychotic agent
- antipsychotic
- therapy
- prophylaxis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【解決手段】ミルタザピンと抗精神病剤の治療用の組み合わせ、並びに該組み合わせを含有する医薬組成物、及び精神異常症の治療または予防におけるそれらの使用。該抗精神病剤が、ハロペリドール、リスペリドン、およびクエチアピンから選択される前記医薬品。
【選択図】なし
Description
使用した試験法は、1976年のProtaisらによる「マウスにおける、アポモルヒネにより誘発される登はん行動(Climbing behaviour induced by apomorphine in mice):線条体のドパミン受容体を調査するための簡易試験(a simple test for the study of dopamine receptors in striatum)、Psychopharmacology 50:1−6」に記載されているものである。体重21g〜25gの雄のマウス(Charles River,Germanyから入手したCrL:CD−1(IcR)BRまたはHarlan OLAC UKから入手したMFI)を用いた。それぞれ10匹のマウスからなるグループに、プラシーボまたはミルタザピンと、ある用量のハロペリドールまたはリスペリドンを同時に皮下(s.c.)注射した。30分後、全てのマウスに1mg/kgまたは0.75mg/kgのアポモルヒネをs.c.注射した。アポモルヒネの注射後、直ちにそれらのマウスをワイヤメッシュ製の筒(直径12cm、高さ14cm)に1匹ずつ入れた。その10分後及び20分後にそれらのマウスの登はん行動を次のように評点する:4本の足が床に着いている=0点;1本乃至2本の足が壁を掴んでいる=1点;3本乃至4本の足が壁を掴んでいる=2点。それぞれのマウスに付き、10分後及び20分後の観察結果の合計点を計算し、各治療グループの平均点を決定する。対照グループの平均点は少なくとも2.0点(可能な最高点数は4.0点である)でなければならない。有意性の示度は両側イェーツ検定で試験する。
ハロペリドール実験の結果が第1/2図に示されている。プラシーボグループの平均点±平均標準誤差(S.E.M.)は3.35±0.20であった。22μg/kg及び46μg/kgのハロペリドール後の平均点±S.E.M.は、それぞれ、3.2±0.33及び2.6±0.37であった。ハロペリドールによる登はん行動の抑制は、マウスがミルタザピン(1mg/kg及び10mg/kg)と同時治療された場合、用量依存的に増強された。ミルタザピンのみを用いた実験の結果は、22mg/kgまでミルタザピンを投与しても、アポモルヒネ誘導登はん行動に効果を及ぼさないことを示した;第2/2図参照。
Claims (1)
- ミルタザピンと抗精神病剤とを異なる医薬処方として含む、精神異常症を治療及び/又は予防するための医薬品であって、該抗精神病剤が、ハロペリドール、リスペリドン、およびクエチアピンから選択される前記医薬品。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97200881 | 1997-03-27 | ||
EP97200881.7 | 1997-03-27 | ||
EP97202785 | 1997-09-11 | ||
EP97202785.8 | 1997-09-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54116898A Division JP4377456B2 (ja) | 1997-03-27 | 1998-03-25 | 精神異常症を治療及び/又は予防するための組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009280596A true JP2009280596A (ja) | 2009-12-03 |
JP5023315B2 JP5023315B2 (ja) | 2012-09-12 |
Family
ID=26146283
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54116898A Expired - Fee Related JP4377456B2 (ja) | 1997-03-27 | 1998-03-25 | 精神異常症を治療及び/又は予防するための組成物 |
JP2009168383A Expired - Fee Related JP5023315B2 (ja) | 1997-03-27 | 2009-07-17 | 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54116898A Expired - Fee Related JP4377456B2 (ja) | 1997-03-27 | 1998-03-25 | 精神異常症を治療及び/又は予防するための組成物 |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP0969845B1 (ja) |
JP (2) | JP4377456B2 (ja) |
KR (1) | KR100577865B1 (ja) |
CN (1) | CN1226036C (ja) |
AR (1) | AR012193A1 (ja) |
AT (1) | ATE318604T1 (ja) |
AU (1) | AU726194B2 (ja) |
BR (1) | BR9808077A (ja) |
CA (1) | CA2284551C (ja) |
CZ (1) | CZ298105B6 (ja) |
DE (1) | DE69833645T2 (ja) |
DK (1) | DK0969845T3 (ja) |
ES (1) | ES2259207T3 (ja) |
HK (1) | HK1023293A1 (ja) |
HU (1) | HUP0002742A3 (ja) |
ID (1) | ID22283A (ja) |
IL (1) | IL123716A (ja) |
NO (1) | NO994673L (ja) |
NZ (1) | NZ337618A (ja) |
PL (1) | PL191449B1 (ja) |
PT (1) | PT969845E (ja) |
RU (1) | RU2222330C2 (ja) |
TR (1) | TR199902334T2 (ja) |
TW (1) | TW587938B (ja) |
WO (1) | WO1998043646A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
US6280763B1 (en) | 1999-05-10 | 2001-08-28 | Pierce Management, Llc | Apparatus and method for transdermal delivery of bupropion |
FR2797399B1 (fr) * | 1999-08-13 | 2002-10-18 | Aventis Pharma Sa | Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines |
FR2802101B1 (fr) * | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
US6350773B1 (en) | 1999-12-10 | 2002-02-26 | American Home Products Corporation | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
RU2268725C2 (ru) | 2000-01-19 | 2006-01-27 | Акцо Нобель Н.В. | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств |
US6495154B1 (en) * | 2000-11-21 | 2002-12-17 | Vivus Inc. | On demand administration of clomipramine and salts thereof to treat premature ejaculation |
ES2284830T3 (es) * | 2001-02-06 | 2007-11-16 | Astrazeneca Ab | Uso de quetiapina para el tratamiento de la cocaina. |
EP1795199A3 (en) * | 2001-02-06 | 2007-07-25 | AstraZeneca AB | Quetiapine for the treatment of substance dependence or substance abuse |
WO2005044262A1 (en) | 2003-10-29 | 2005-05-19 | Wyeth | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof |
US7855195B2 (en) | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
EP1547650A1 (en) * | 2003-12-02 | 2005-06-29 | B & B Beheer NV | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
DK1541197T3 (da) * | 2003-12-02 | 2009-06-15 | Pharmaneuroboost N V | Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser |
US7884096B2 (en) | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US8304431B2 (en) | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
WO2005117916A1 (en) | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with cisplatin and an egfr-inhibitor |
JP5001271B2 (ja) * | 2006-06-09 | 2012-08-15 | 大日本住友製薬株式会社 | 新規テープ製剤 |
AR085840A1 (es) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona |
DE102012011839B4 (de) | 2012-06-14 | 2018-03-22 | Norbert Müller | Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen |
RU2509560C1 (ru) * | 2013-03-22 | 2014-03-20 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Новые терапевтические комбинации миртазапина для применения при болевых расстройствах |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01216933A (ja) * | 1988-01-15 | 1989-08-30 | F Hoffmann La Roche Ag | 薬剤 |
JPH05262651A (ja) * | 1989-12-06 | 1993-10-12 | Akzo Nv | 向精神薬の安定化溶液 |
WO1994010982A1 (en) * | 1992-11-17 | 1994-05-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained-release microsphere containing antipsychotic and process for producing the same |
JPH07242669A (ja) * | 1994-03-07 | 1995-09-19 | Akikazu Ogawa | 四環系とブチロフェノン誘導体を化学結合した化合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2410821A1 (de) * | 1974-03-07 | 1975-09-18 | Hoechst Ag | Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung |
ZA935078B (en) * | 1992-07-15 | 1994-02-07 | Nicolaas Johannes Jaco Loetter | Pharmaceutical composition |
-
1998
- 1998-03-17 TW TW087103929A patent/TW587938B/zh not_active IP Right Cessation
- 1998-03-17 IL IL12371698A patent/IL123716A/xx not_active IP Right Cessation
- 1998-03-25 PT PT98919209T patent/PT969845E/pt unknown
- 1998-03-25 DK DK98919209T patent/DK0969845T3/da active
- 1998-03-25 ES ES98919209T patent/ES2259207T3/es not_active Expired - Lifetime
- 1998-03-25 CZ CZ0343199A patent/CZ298105B6/cs not_active IP Right Cessation
- 1998-03-25 EP EP98919209A patent/EP0969845B1/en not_active Expired - Lifetime
- 1998-03-25 KR KR1019997008745A patent/KR100577865B1/ko not_active IP Right Cessation
- 1998-03-25 CA CA002284551A patent/CA2284551C/en not_active Expired - Fee Related
- 1998-03-25 DE DE69833645T patent/DE69833645T2/de not_active Expired - Lifetime
- 1998-03-25 JP JP54116898A patent/JP4377456B2/ja not_active Expired - Fee Related
- 1998-03-25 RU RU99122597/14A patent/RU2222330C2/ru not_active IP Right Cessation
- 1998-03-25 HU HU0002742A patent/HUP0002742A3/hu unknown
- 1998-03-25 ID IDW991022A patent/ID22283A/id unknown
- 1998-03-25 WO PCT/EP1998/001920 patent/WO1998043646A1/en active IP Right Grant
- 1998-03-25 AT AT98919209T patent/ATE318604T1/de not_active IP Right Cessation
- 1998-03-25 CN CNB98803770XA patent/CN1226036C/zh not_active Expired - Fee Related
- 1998-03-25 BR BR9808077-6A patent/BR9808077A/pt not_active Application Discontinuation
- 1998-03-25 AU AU72139/98A patent/AU726194B2/en not_active Ceased
- 1998-03-25 PL PL335890A patent/PL191449B1/pl unknown
- 1998-03-25 TR TR1999/02334T patent/TR199902334T2/xx unknown
- 1998-03-25 NZ NZ337618A patent/NZ337618A/en unknown
- 1998-03-27 AR ARP980101406A patent/AR012193A1/es not_active Application Discontinuation
-
1999
- 1999-09-24 NO NO19994673A patent/NO994673L/no not_active Application Discontinuation
-
2000
- 2000-05-02 HK HK00102643A patent/HK1023293A1/xx not_active IP Right Cessation
-
2009
- 2009-07-17 JP JP2009168383A patent/JP5023315B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01216933A (ja) * | 1988-01-15 | 1989-08-30 | F Hoffmann La Roche Ag | 薬剤 |
JPH05262651A (ja) * | 1989-12-06 | 1993-10-12 | Akzo Nv | 向精神薬の安定化溶液 |
WO1994010982A1 (en) * | 1992-11-17 | 1994-05-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained-release microsphere containing antipsychotic and process for producing the same |
JPH07242669A (ja) * | 1994-03-07 | 1995-09-19 | Akikazu Ogawa | 四環系とブチロフェノン誘導体を化学結合した化合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5023315B2 (ja) | 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ | |
US6150353A (en) | Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders | |
US10716785B2 (en) | Methods for treating antipsychotic-induced weight gain | |
CZ284363B6 (cs) | Použití protikřečových činidel k přípravě léčiv určených k léčení Parkinsonovy choroby a Parkinsonových syndromů | |
JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
JP2006083190A (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
JP2008525413A (ja) | 双極性障害を治療するための単剤としてのサブコメリン、または、気分安定剤または抗躁病薬と併用されるサブコメリン | |
ZA200509904B (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
KR20020015329A (ko) | 멜라토닌의 치료학적 용도 | |
ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
JP2003509467A5 (ja) | ||
CN101247796A (zh) | 用于治疗精神病的组合物 | |
EP1359919A1 (en) | Method of treating substance abuse with quetiapine | |
MXPA99008791A (en) | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders | |
JP2019001830A (ja) | 医薬 | |
AR020167A1 (es) | Metodo para la prevencion del inicio del asma | |
RU98109932A (ru) | Применение 1-(2-нафт-2-илэтил)-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина для получения лекарственных средств, предназначенных для лечения бокового амиотрафического склероза | |
EP0998923A1 (en) | Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias | |
EP1795199A2 (en) | Quetiapine for the treatment of substance dependence or substance abuse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20120308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120403 |
|
TRDD | Decision of grant or rejection written | ||
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120423 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120424 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120523 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150629 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |